We are transforming the future of healthcare by predicting those most at genetic risk for developing late-onset Alzheimer’s disease
Cytox’s polygenic risk scoring approaches help pharmaceutical and biotech companies cost-effectively and accurately stratify candidates for clinical trials
Services include genetic risk assessment for amyloid status and cognitive decline, as well as mTOR-associated pathway analysis profiling for more accurate drug targeting
We are transforming the future of healthcare by predicting those most at genetic risk for developing late-onset Alzheimer’s disease
Cytox’s polygenic risk scoring approaches help pharmaceutical and biotech companies cost-effectively and accurately stratify candidates for clinical trials
Services include genetic risk assessment for amyloid status and cognitive decline, as well as mTOR-associated pathway analysis profiling for more accurate drug targeting
LATEST NEWS
Sep 21, 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of the first, physician use only, polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease